Table 4.
Treatment is displayed for each year in the 10-year period from 2004 to 2013 for patients with rheumatoid arthritis monitored with outcome measures in an ordinary outpatient clinic
| Treatment | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | P value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| (n = 404) | (n = 604) | (n = 620) | (n = 743) | (n = 796) | (n = 969) | (n = 1069) | (n = 1103) | (n = 1113) | (n = 1083) | (2010–2013) | |
| No treatmenta | 44 (10.9) | 102 (16.9) | 94 (15.2) | 110 (14.8) | 99 (12.4) | 139 (14.3) | 122 (11.4) | 121 (11.0) | 132 (11.9) | 106 (9.8) | 0.45 |
| Biologic DMARDs (%) | 141 (34.9) | 170 (28.1) | 161 (26.0) | 203 (27.3) | 234 (29.4) | 265 (27.3) | 335 (31.3) | 342 (31.0) | 366 (32.9) | 373 (34.4) | 0.30 |
| TNF inhibitor | 139 (34.4) | 170 (28.1) | 159 (25.6) | 176 (23.7) | 192 (24.1) | 198 (20.4) | 236 (22.1) | 221 (20.0) | 230 (20.7) | 227 (21.0) | 0.70 |
| Non-TNF inhibitors | 2 (0.5) | 0 (0) | 2 (0.3) | 27 (3.6) | 42 (5.3) | 67 (6.9) | 99 (9.3) | 121 (11.0) | 136 (12.2) | 146 (13.5) | 0.016 |
| Synthetic DMARDs (%) | 267 (66.1) | 349 (58.8) | 351 (56.6) | 440 (59.2) | 471 (59.2) | 562 (58.0) | 627 (58.7) | 667 (60.5) | 668 (60.0) | 660 (60.9) | 0.73 |
| One synthetic DMARD (%) | 243 (60.1) | 321 (53.1) | 342 (55.2) | 423 (56.9) | 455 (57.2) | 547 (56.4) | 612 (57.2) | 648 (58.7) | 649 (58.3) | 649 (59.9) | 0.88 |
| Two synthetic DMARDs (%) | 24 (5.9) | 28 (4.6) | 9 (1.5) | 16 (2.2) | 16 (2.0) | 14 (1.4) | 14 (1.3) | 18 (1.6) | 17 (1.5) | 10 (0.9) | |
| Three synthetic DMARDs (%) | 0 (0) | 0 (0) | 0 (0) | 1 (0.1) | 0 (0) | 1 (0.1) | 1 (0.1) | 1 (0.1) | 2 (0.2) | 1 (0.1) | |
| Biologic and synthetic DMARDs | 100 (24.8) | 123 (20.4) | 114 (18.4) | 142 (19.1) | 155 (19.5) | 176 (18.2) | 216 (20.2) | 226 (20.5) | 234 (21.0) | 233 (21.5) | 0.58 |
| TNF inhibitor and synthetic DMARDs | 99 (24.5) | 123 (20.4) | 113 (18.2) | 129 (17.4) | 132 (16.6) | 145 (15.0) | 167 (15.6) | 170 (15.4) | 170 (15.3) | 162 (15.0) | 0.94 |
| Prednisolone (%) | 224 (55.4) | 334 (55.3) | 369 (59.5) | 433 (58.3) | 486 (61.1) | 589 (60.8) | 653 (61.1) | 653 (59.2) | 617 (55.4) | 590 (54.5) | 0.005 |
| Prednisolone and synthetic DMARDs (%) | 152 (37.6) | 208 (34.4) | 216 (34.8) | 270 (36.3) | 297 (37.3) | 354 (36.5) | 377 (35.3) | 394 (35.7) | 368 (33.1) | 346 (31.9) | 0.43 |
| Biologic DMARD and prednisolone | 53 (13.1) | 61 (10.1) | 57 (9.2) | 78 (10.5) | 90 (11.3) | 101 (10.4) | 125 (11.7) | 125 (11.3) | 124 (11.1) | 120 (11.1) | 0.80 |
| Biologic DMARDs | |||||||||||
| Adalimumab (%) | 27 (6.7) | 50 (8.3) | 51 (8.2) | 56 (7.5) | 58 (7.3) | 80 (8.3) | 78 (7.3) | 70 (6.3) | 61 (5.5) | 52 (4.8) | 0.08 |
| Certolizumab (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 8 (0.7) | 10 (0.9) | 21 (1.9) | 44 (4.1) | 0.000 |
| Etanercept (%) | 60 (14.9) | 77 (12.7) | 68 (11.0) | 73 (9.8) | 96 (12.1) | 88 (9.1) | 98 (9.2) | 109 (9.9) | 118 (10.6) | 104 (9.6) | 0.72 |
| Golimumab (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 26 (2.4) | 14 (1.3) | 12 (1.1) | 9 (0.8) | 0.008 |
| Infliximab (%) | 52 (12.9) | 43 (7.1) | 40 (6.5) | 47 (6.3) | 38 (4.8) | 30 (3.1) | 26 (2.4) | 18 (1.6) | 18 (1.6) | 18 (1.7) | 0.42 |
| Abatacept (%) | 0 (0) | 0 (0) | 0 (0) | 3 (0.4) | 3 (0.4) | 5 (0.5) | 11 (1.0) | 21 (1.9) | 23 (2.1) | 15 (1.4) | 0.19 |
| Anakinra (%) | 2 (0.5) | 0 (0) | 1 (0.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | – |
| Rituximab (%) | 0 (0) | 0 (0) | 1 (0.2) | 24 (3.2) | 39 (4.9) | 58 (6.0) | 76 (7.1) | 88 (8.0) | 102 (9.2) | 118 (10.9) | 0.013 |
| Tocilizumab (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (0.4) | 12 (1.1) | 12 (1.1) | 11 (1.0) | 13 (1.2) | 0.97 |
| Synthetic DMARDs | |||||||||||
| Leflunomide (%) | 15 (3.7) | 31 (5.1) | 29 (4.7) | 40 (5.4) | 44 (5.5) | 55 (5.7) | 63 (5.9) | 64 (5.8) | 62 (5.6) | 58 (5.4) | 0.95 |
| Methotrexate (%) | 212 (52.5) | 269 (44.5) | 275 (44.4) | 349 (47.0) | 360 (45.2) | 438 (45.2) | 496 (46.4) | 544 (49.3) | 558 (50.1) | 551 (50.9) | 0.17 |
| Methotrexate dose weekly (mg) | 10.0 (2.3) | 10.2 (2.7) | 10.6 (2.6) | 10.8 (2.8) | 11.3 (3.0) | 11.9 (3.0) | 12.3 (3.4) | 12.6 (3.4) | 13.2 (3.6) | 13.5 (3.8) | <0.001 |
| Sulfasalazine (%) | 12 (3.0) | 20 (3.3) | 21 (3.4) | 27 (3.6) | 31 (3.9) | 31 (3.2) | 39 (3.6) | 36 (3.3) | 32 (2.9) | 39 (3.6) | 0.73 |
| Hydroxychloroquine (%) | 37 (9.2) | 42 (7.0) | 24 (3.9) | 30 (4.0) | 35 (4.4) | 39 (4.0) | 36 (3.4) | 35 (3.2) | 31 (2.8) | 20 (1.8) | 0.14 |
| Other synthetic DMARDsb (%) | 15 (3.7) | 15 (2.5) | 11 (1.8) | 11 (1.5) | 16 (2.0) | 14 (1.4) | 9 (0.8) | 7 (0.6) | 5 (0.4) | 3 (0.3) | 0.32 |
Abbreviations: DMARDs disease-modifying antirheumatic drugs, TNF tumor necrosis factor
Data are presented as numbers and percentages (%) or as mean with standard deviation
χ2 test or linear regression used to test for differences during follow-up for the period from 2010 to 2013
aNo prednisolone, biologic or synthetic DMARDs
bAuranofin, azathioprine, ciclosporin and gold